Search

Your search keyword '"Garigliany, Mutien"' showing total 328 results
Start Over Author "Garigliany, Mutien"
328 results on '"Garigliany, Mutien"'

7. West Nile and Usutu viruses: current spreading and future threats in a warming northern Europe.

Author

Laverdeur, Justine, Amory, Hélène, Beckers, Pablo, Desmecht, Daniel, Francis, Frédéric, Garigliany, Mutien-Marie, Hayette, Marie-Pierre, Linden, Annick, and Darcis, Gilles

Subjects
WEST Nile virus, ARBOVIRUS diseases, ARTHROPOD vectors, CLIMATE change, PUBLIC health
Abstract

Climate change heavily threatens planetary and human health. Arboviral infections are best studied using the One Health concept, due to their reliance on complex interactions between environmental factors, arthropod vectors and vertebrate hosts. This review focuses on two arboviruses, namely West Nile Virus (WNV) and Usutu Virus (USUV), both causing emerging public health issues in northern Europe. They are both maintained in an enzootic cycle involving birds and Culex spp mosquitoes. WNV has demonstrated its sensitivity to the consequences of climate change and there is already evidence that global warming contributes to its expansion in Europe. Future WNV indigenous transmission in northern Europe is therefore plausible. Usutu is a lesser known arbovirosis, sharing similar vectors and hosts as WNV. USUV has a similar geographic expansion to WNV, exhibiting some level of co-circulation. It is therefore crucial to monitor these viruses in the hitherto relatively spared regions of northern Europe. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

11. Effect of fatty acid-enriched black soldier fly larvae meal combined with chitinase on the metabolic processes of Nile tilapia

Author

Agbohessou, Pamphile S., primary, Mandiki, Robert, additional, Mes, Wouter, additional, Blanquer, Aude, additional, Gérardy, Mazarine, additional, Garigliany, Mutien-Marie, additional, Lambert, Jérôme, additional, Cambier, Pierre, additional, Tokpon, Nicole, additional, Lalèyè, Philippe A., additional, and Kestemont, Patrick, additional

Published
2024
Full Text
View/download PDF

12. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

13. Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

Author

Misset, Benoît, Hoste, Eric, Donneau, Anne Françoise, Grimaldi, David, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Garigliany, Mutien, Najdovski, Tome, and Laterre, Pierre François

Published
2021
Full Text
View/download PDF

14. Fibroblast activation protein is a cellular marker of fibrotic activity in canine idiopathic pulmonary fibrosis.

Author

Rizzoli, Elodie, de Meeûs d'Argenteuil, Constance, Fastrès, Aline, Roels, Elodie, Janssen, Pierre, Puré, Ellen, Garigliany, Mutien-Marie, Marichal, Thomas, and Clercx, Cécile

Subjects
IDIOPATHIC pulmonary fibrosis, PULMONARY fibrosis, INTERSTITIAL lung diseases, ENZYME-linked immunosorbent assay, FIBROBLASTS, ETIOLOGY of diseases
Abstract

Canine idiopathic pulmonary fibrosis (CIPF) is a progressive fibrotic interstitial lung disease of unknown etiology, afflicting aging West Highland white terriers (WHWTs) and leading to progressive respiratory failure. Fibroblast activation protein (FAP), a protease overexpressed in many cancers, is upregulated in idiopathic pulmonary fibrosis in humans. The aim of this study was to investigate FAP as a marker of active fibrosis in lung biopsies from WHWTs affected with CIPF, as well as the potential of plasmatic FAP as a biomarker. After establishing a scoring system to evaluate the severity and activity of fibrosis on histopathological lung sections, anti-FAP immunohistochemistry was performed on healthy and CIPF samples. FAP expression was characterized using both visual and digital quantitative pathology software analyses and then correlated to fibrosis severity and activity. Levels of plasmatic FAP in WHWTs affected with CIPF were measured by enzyme-linked immunosorbent assay and compared with healthy dogs. Lung samples from 22 WHWTs affected with CIPF were collected. According to the fibrosis scoring system, they were classified as cases of mild (5), moderate (9) and severe (8) fibrosis and were attributed scores of fibrosis activity. Fifteen healthy lung samples were classified as non-fibrotic. Healthy lung samples were FAP-negative, whereas fibroblasts were FAP-positive in 20 CIPF samples. FAP immunohistochemical expression correlated mildly with fibrosis severity (p  <  0.05; R²   =  0.22) but highly with fibrosis activity scores (p  <  0.001; R²   =  0.68). Digital image analysis detected a higher percentage of FAP-positive cells in areas of active fibrosis (p  <  0.001) and FAP positive cells were distributed outside mature fibrosis lesions, clustered in active fibrosis areas or scattered within alveolar septa. On the other hand, plasmatic FAP was significantly lower in dogs affected with CIPF compared with healthy dogs (p  <  0.01). In conclusion, this study provides a valuable histological scoring system to assess the severity and activity of fibrosis in CIPF. It demonstrates that FAP is a good cellular marker of fibrotic activity in CIPF, and thus constitutes a promising target to be exploited for diagnostic and therapeutic applications. Additionally, it suggests that plasmatic FAP, although non-specific, could be altered in CIPF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Recruited atypical Ly6G+ macrophages license alveolar regeneration after lung injury.

Author

Ruscitti, Cecilia, Abinet, Joan, Maréchal, Pauline, Meunier, Margot, de Meeûs, Constance, Vanneste, Domien, Janssen, Pierre, Dourcy, Mickael, Thiry, Marc, Bureau, Fabrice, Schneider, Christoph, Machiels, Benedicte, Hidalgo, Andres, Ginhoux, Florent, Dewals, Benjamin G., Guiot, Julien, Schleich, Florence, Garigliany, Mutien-Marie, Bellahcène, Akeila, and Radermecker, Coraline

Subjects
GRANULOCYTE-macrophage colony-stimulating factor, MYELOID cells, ALVEOLAR macrophages, CELL populations, EPITHELIAL cells
Abstract

The lung is constantly exposed to airborne pathogens and particles that can cause alveolar damage. Hence, appropriate repair responses are essential for gas exchange and life. Here, we deciphered the spatiotemporal trajectory and function of an atypical population of macrophages after lung injury. Post–influenza A virus (IAV) infection, short-lived monocyte-derived Ly6G-expressing macrophages (Ly6G+ Macs) were recruited to the alveoli of lung perilesional areas. Ly6G+ Macs engulfed immune cells, exhibited a high metabolic potential, and clustered with alveolar type 2 epithelial cells (AT2s) in zones of active epithelial regeneration. Ly6G+ Macs were partially dependent on granulocyte-macrophage colony-stimulating factor and interleukin-4 receptor signaling and were essential for AT2-dependent alveolar regeneration. Similar macrophages were recruited in other models of injury and in the airspaces of lungs from patients with suspected pneumonia. This study identifies perilesional alveolar Ly6G+ Macs as a spatially restricted, short-lived macrophage subset promoting epithelial regeneration postinjury, thus representing an attractive therapeutic target for treating lung damage. Editor's summary: Respiratory virus infections can cause long-lasting lung damage, but how specific lung myeloid cell populations contribute to postinfection recovery is not fully understood. Using a mouse model of influenza A virus infection, Ruscitti et al. identified a distinct population of Ly6G+ monocyte-derived macrophages that emerges during the early recovery phase after viral-triggered lung injury. Ly6G+ lung macrophages were short lived and highly phagocytic and populated the alveoli within perilesional areas undergoing regeneration. Genetically engineered mice lacking lung Ly6G+ macrophages displayed impaired epithelial regeneration after influenza infection. Together, these findings identify a previously unappreciated population of reparative lung macrophages that could be targeted therapeutically to treat lung damage. —Claire Olingy [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Zoonotic pathogens in wild Asian primates: a systematic review highlighting research gaps.

Author

Patouillat, Laurie, Hambuckers, Alain, Subrata, Sena Adi, Garigliany, Mutien, and Brotcorne, Fany

Subjects
EVIDENCE gaps, PRIMATES, MAMMAL parasites, PATHOGENIC microorganisms, SPECIES diversity
Abstract

Introduction: Ongoing global changes, including natural land conversion for agriculture and urbanization, modify the dynamics of human–primate contacts, resulting in increased zoonotic risks. Although Asia shelters high primate diversity and experiences rapid expansion of human–primate contact zones, there remains little documentation regarding zoonotic surveillance in the primates of this region. Methods: Using the PRISMA guidelines, we conducted a systematic review to compile an inventory of zoonotic pathogens detected in wild Asian primates, while highlighting the coverage of primate species, countries, and pathogen groups surveyed, as well as the diagnostic methods used across the studies. Moreover, we compared the species richness of pathogens harbored by primates across diverse types of habitats classified according to their degree of anthropization (i.e., urban vs. rural vs. forest habitats). Results and discussion: Searches of Scopus, PubMed, and the Global Mammal Parasite Database yielded 152 articles on 39 primate species. We inventoried 183 pathogens, including 63 helminthic gastrointestinal parasites, two blood-borne parasites, 42 protozoa, 45 viruses, 30 bacteria, and one fungus. Considering each study as a sample, species accumulation curves revealed no significant differences in specific richness between habitat types for any of the pathogen groups analyzed. This is likely due to the insufficient sampling effort (i.e., a limited number of studies), which prevents drawing conclusive findings. This systematic review identified several publication biases, particularly the uneven representation of host species and pathogen groups studied, as well as a lack of use of generic diagnostic methods. Addressing these gaps necessitates a multidisciplinary strategy framed in a One Health approach, which may facilitate a broader inventory of pathogens and ultimately limit the risk of cross-species transmission at the human–primate interface. Strengthening the zoonotic surveillance in primates of this region could be realized notably through the application of more comprehensive diagnostic techniques such as broad-spectrum analyses without a priori selection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

Author

Misset, Benoît, primary, Piagnerelli, Michael, additional, Hoste, Eric, additional, Dardenne, Nadia, additional, Grimaldi, David, additional, Michaux, Isabelle, additional, De Waele, Elisabeth, additional, Dumoulin, Alexander, additional, Jorens, Philippe G., additional, van der Hauwaert, Emmanuel, additional, Vallot, Frédéric, additional, Lamote, Stoffel, additional, Swinnen, Walter, additional, De Schryver, Nicolas, additional, Fraipont, Vincent, additional, de Mey, Nathalie, additional, Dauby, Nicolas, additional, Layios, Nathalie, additional, Mesland, Jean-Baptiste, additional, Meyfroidt, Geert, additional, Moutschen, Michel, additional, Compernolle, Veerle, additional, Gothot, André, additional, Desmecht, Daniel, additional, Taveira da Silva Pereira, Maria I., additional, Garigliany, Mutien, additional, Najdovski, Tome, additional, Bertrand, Axelle, additional, Donneau, Anne-Françoise, additional, and Laterre, Pierre-François, additional

Published
2023
Full Text
View/download PDF

21. Molecular detection and associated risk factors of Anaplasma marginale, A. ovis and A. platys in sheep from Algeria with evidence of the absence of A. phagocytophilum

Author

Chadi, Hafidha, primary, Moraga-Fernández, Alberto, additional, Sánchez-Sánchez, Marta, additional, Chenchouni, Haroun, additional, Fernández de Mera, Isabel G., additional, Garigliany, Mutien-Marie, additional, de la Fuente, José, additional, Tennah, Safia, additional, Sedrati, Tahar, additional, and Ghalmi, Farida, additional

Published
2023
Full Text
View/download PDF

22. SARS-CoV-2 Natural Transmission from Human to Cat, Belgium, March 2020

Author

Garigliany, Mutien, Van Laere, Anne-Sophie, Clercx, Cecile, Giet, Didier, Escriou, Nicolas, Huon, Christele, van der Werf, Sylvie, Eloit, Marc, and Desmecht, Daniel

Subjects
Diagnosis, Case studies, Health aspects, Causes of, Disease transmission -- Case studies -- Causes of, Domestic cats -- Case studies -- Health aspects, Pet owners -- Case studies -- Health aspects, COVID-19 -- Case studies -- Diagnosis, Cats -- Case studies -- Health aspects
Abstract

We report the investigation of illness and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a household cat in Belgium (1). The cat was a female domestic shorthair, [...]

Published
2020
Full Text
View/download PDF

23. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

Author

Misset, Benoît, Hoste, Eric, Donneau, Anne-Françoise, Grimaldi, David, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Garigliany, Mutien, Najdovski, Tome, and Laterre, Pierre-François

Published
2020
Full Text
View/download PDF

26. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

Author

Misset, Benoit, Piagnerelli, Michaël, Hoste, Eric, Dardenne, Nadia, Grimaldi, David, Michaux, Isabelle, De Waele, Elisabeth, Dumoulin, Alexander, Jorens, Philippe G, van der Hauwaert, Emmanuel, Vallot, Frédéric, Lamote, Stoffel, Swinnen, Walter, De Schryver, Nicolas, Fraipont, Vincent, de Mey, Nathalie, Dauby, Nicolas, Layios, Nathalie, Mesland, Jean Baptiste, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Taveira da Silva Pereira, Maria, Garigliany, Mutien, Najdovski, Tome, Bertrand, Axelle, Donneau, Anne-Françoise, Laterre, Pierre-Francois, Misset, Benoit, Piagnerelli, Michaël, Hoste, Eric, Dardenne, Nadia, Grimaldi, David, Michaux, Isabelle, De Waele, Elisabeth, Dumoulin, Alexander, Jorens, Philippe G, van der Hauwaert, Emmanuel, Vallot, Frédéric, Lamote, Stoffel, Swinnen, Walter, De Schryver, Nicolas, Fraipont, Vincent, de Mey, Nathalie, Dauby, Nicolas, Layios, Nathalie, Mesland, Jean Baptiste, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Taveira da Silva Pereira, Maria, Garigliany, Mutien, Najdovski, Tome, Bertrand, Axelle, Donneau, Anne-Françoise, and Laterre, Pierre-Francois

Abstract

Background Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent plasma in patients with Covid-19-induced acute respiratory distress syndrome (ARDS). Methods In this open-label trial, we randomly assigned adult patients with Covid-19-induced ARDS who had been receiving invasive mechanical ventilation for less than 5 days in a 1:1 ratio to receive either convalescent plasma with a neutralizing antibody titer of at least 1:320 or standard care alone. Randomization was stratified according to the time from tracheal intubation to inclusion. The primary outcome was death by day 28. Results A total of 475 patients underwent randomization from September 2020 through March 2022. Overall, 237 patients were assigned to receive convalescent plasma and 238 to receive standard care. Owing to a shortage of convalescent plasma, a neutralizing antibody titer of 1:160 was administered to 17.7% of the patients in the convalescent-plasma group. Glucocorticoids were administered to 466 patients (98.1%). At day 28, mortality was 35.4% in the convalescent-plasma group and 45.0% in the standard-care group (P=0.03). In a prespecified analysis, this effect was observed mainly in patients who underwent randomization 48 hours or less after the initiation of invasive mechanical ventilation. Serious adverse events did not differ substantially between the two groups. Conclusions The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly reduced mortality at day 28. This effect was mainly observed in patients who underwent randomization 48 hours or less after ventilation initiation. (Funded by the Belgian Health Care Knowledge Center; ClinicalTrials.gov number, NCT0, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

30. First report of Bovine Viral Diarrhea Virus subgenotypes 1d and 1e in Southern Chile

Author

Hugues, Florence, primary, Cabezas, Ignacio, additional, Garigliany, Mutien, additional, Rivas, Felipe, additional, Casanova, Tomás, additional, González, Eddy E., additional, Sánchez, Oliberto, additional, Castillo, Raúl, additional, Parra, Natalie C., additional, Inostroza-Michael, Oscar, additional, Moreno, Lucila, additional, Hernández, Cristián E., additional, and Toledo, Jorge R., additional

Published
2023
Full Text
View/download PDF

32. Phylogeographic Analysis of African Swine Fever Virus, Western Europe, 2018

Author

Garigliany, Mutien, Desmecht, Daniel, Tignon, Marylene, Cassart, Dominique, Lesenfant, Christophe, Paternostre, Julien, Volpe, Rosario, Cay, Ann Brigitte, van den Berg, Thierry, and Linden, Annick

Subjects
Natural history, Analysis, Diseases, Hog cholera -- Analysis, Phylogeny -- Analysis, Swine -- Analysis, Labor unions, DNA
Abstract

African swine fever (ASF) is a devastating disease of domestic pigs and wild boars caused by a DNA arbovirus, African swine fever virus (ASFV), belonging to the family Asfarviridae. ASF [...]

Published
2019
Full Text
View/download PDF

33. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Author

Devos, Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tomé, Romano, Marta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler, Lucie, Moonen, Martial, Moutschen, Michel, Van Regenmortel, Niels, Ariën, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias M., Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, Meyfroidt, Geert, DAWn-plasma investigators, [ missing ], Gyselinck, Iwein/0000-0002-4068-7228, Barbezange, Cyril/0000-0001-9606-2983, Dauby, Nicolas/0000-0002-7697-6849, Liesenborghs, Laurens/0000-0001-5616-8548, Devos , Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tome, Romano, Marta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler , Lucie, Moonen , Martial, Moutschen, Michel, Van Regenmortel, Niels, Arien, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias M., Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, Meyfroidt, Geert, DAWn-plasma investigators, Faculty of Sciences and Bioengineering Sciences, Internal Medicine, Internal Medicine Specializations, and Clinical sciences

Subjects
Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Convalescent plasma, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Antibodies, Viral, Antibodies, Viral/blood, Internal medicine, medicine, Medicine and Health Sciences, Humans, Prospective Studies, Antibodies, Neutralizing/blood, Adverse effect, Mechanical ventilation, biology, business.industry, Immunization, Passive, COVID-19, Odds ratio, Sciences bio-médicales et agricoles, Antibodies, Neutralizing, Clinical trial, Hospitalization, Treatment Outcome, DAWn-plasma investigators, biology.protein, Human medicine, Antibody, business, COVID-19/therapy
Abstract

Background Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness. Methods In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study. Results Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%). Conclusions Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality., info:eu-repo/semantics/published

Published
2022

35. Putative lineage of novel African Usutu virus, central Europe

Author

Cadar, Daniel, Bosch, Stefan, Jost, Hanna, Borstler, Jessica, Garigliany, Mutien-Marie, Becker, Norbert, and Schmidt-Chanasit, Jonas

Subjects
Diseases, Analysis, Bird populations -- Analysis, Phylogeny -- Analysis, Genomics -- Analysis, Genomics, Bird populations, Phylogeny
Abstract

Originally isolated from a Culex neavei mosquito in South Africa in 1959 (1,2), Usutu virus (USUV) was subsequently detected in different mosquito and bird species throughout Sub-Saharan countries (3). USUV [...]

Published
2015
Full Text
View/download PDF

38. A High-Quality Genome Assembly of Striped Catfish (Pangasianodon hypophthalmus) Based on Highly Accurate Long-Read HiFi Sequencing Data

Author

Hai, Dao Minh, primary, Yen, Duong Thuy, additional, Liem, Pham Thanh, additional, Tam, Bui Minh, additional, Huong, Do Thi Thanh, additional, Hang, Bui Thi Bich, additional, Hieu, Dang Quang, additional, Garigliany, Mutien-Marie, additional, Coppieters, Wouter, additional, Kestemont, Patrick, additional, Phuong, Nguyen Thanh, additional, and Farnir, Frédéric, additional

Published
2022
Full Text
View/download PDF

40. University population-based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULiège): a study protocol

Author

Donneau, Anne-Françoise, Guillaume, Michèle, Bours, Vincent, Dandoy, Margaux, Darcis, Gilles, Desmecht, Daniel, Diep, Anh Nguyet, Fievez, Laurence, Garigliany, Mutien-Marie, Gillain, Nicolas, Husson, Eddy, Michel, Fabienne, Moutschen, Michel, Paridans, Marine, Benoît, Pétre, Sabatel, Catherine, Saegerman, Claude, Tytgat, Amandine, Gillet, Laurent, and Bureau, Fabrice

Subjects
Epidemiology, SARS-CoV-2, public health, COVID-19, General Medicine, immunology, Cohort Studies, Seroepidemiologic Studies, Humans, Medicine, Prospective Studies, Vaccination Hesitancy, Pandemics
Abstract

IntroductionFor a safe and sustainable return to normal functioning of academic activities in higher education, objective-driven testing strategies that are flexible and rapidly adaptable are essential to effectively monitor and respond to new developments of the COVID-19 pandemic. To date, prospective longitudinal research on SARS-CoV-2 antibody testing in saliva and seroprevalence in higher education contexts is substantially lacking, limiting our understanding of COVID-19 prevalence, incidence and nature of the immune response to SARS-CoV-2 at various stages of the infection and vaccination. To address this lack of evidence, a prospective population-based cohort study (SARSSURV-ULiège) has recently been started.Methods and analysisStudents (n=1396) and staff members (n=1143) of the University of Liège are followed up over more than 1 year. All participants are required to complete anamnestic, clinical and vaccine hesitancy questionnaires for medical histories and undertaken treatments. Previous proven or suspected SARS-CoV-2 infection is also registered. In phase 1, weekly saliva samples to perform RT-qPCR to detect SARS-CoV-2 and monthly COVID-19 serological rapid test results are collected. Once being positive to either saliva RT-qPCR assay for SARS-CoV-2 presence or to serological test, the participant is invited to enter phase 2. If participants get vaccinated during the study period, they are invited to phase 2. In this second phase, besides weekly saliva self-test, depending on the participants’ profiles, both gargle and blood samples are collected to obtain various biological data to measure the presence of neutralising antibodies against SARS-CoV-2, determine the magnitude and the duration of antibody responses over time.Ethics and disseminationThe study has received the approval from the University Hospital of Liège Ethics Committee (reference number 2021/96, dated 26 March 2021). Potential protocol amendments will be presented to the Research Ethics Committee. The findings of the present study will be presented at scientific conferences and the results published in peer-review publications. Weekly reports will be submitted to the risk assessment group and the risk management group against COVID-19 of the university to enable a timely public health action if necessary.

Published
2022

41. Natural intrauterine infection with Schmallenberg virus in malformed newborn calves

Author

Bayrou, Calixte, Garigliany, Mutien-Marie, Sarlet, Michael, Sartelet, Arnaud, Cassart, Dominique, and Desmecht, Daniel

Subjects
Health aspects, Cattle -- Health aspects, Cattle industry -- Health aspects, Resveratrol -- Health aspects, Livestock industry -- Health aspects
Abstract

During summer and fall 2011, a nonspecific febrile syndrome characterized by hyperthermia and decreased milk production was reported in adult dairy cows from farms in the Netherlands and Germany (1,2). [...]

Published
2014
Full Text
View/download PDF

43. In vitro antiviral activity against SARS‐CoV‐2 of 28 Strychnos extracts

Author

Ledoux, Allison, primary, Leka, Kristi, additional, Bonnet, Olivier, additional, Blanquer, Aude, additional, Alembert, Tiabou Tchinda, additional, da Silva Mirowski, Patrick, additional, de Oliveira Figueiredo, Patricia, additional, Desmecht, Daniel, additional, Garigliany, Mutien‐Marie, additional, and Frédérich, Michel, additional

Published
2022
Full Text
View/download PDF

45. Influenza a strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice

Author

Garigliany, Mutien-Marie, Habyarimana, Adelite, Lambrecht, Benedicte, Van de Paar, Els, Cornet, Anne, van den Berg, Thierry, and Desmecht, Daniel

Subjects
Health aspects, Influenza viruses -- Health aspects, Avian influenza -- Health aspects, Infection -- Health aspects, House mouse -- Health aspects, Mice -- Health aspects
Abstract

According to the World Health Organization, influenza annually infects 5%-15% of the global population, causing 3-5 million cases of severe illness and ≅ 500,000 reported deaths. The persistence of influenza [...]

Published
2010
Full Text
View/download PDF

46. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Author

Devos, Timothy, primary, Van Thillo, Quentin, additional, Compernolle, Veerle, additional, Najdovski, Tomé, additional, Romano, Marta, additional, Dauby, Nicolas, additional, Jadot, Laurent, additional, Leys, Mathias, additional, Maillart, Evelyne, additional, Loof, Sarah, additional, Seyler, Lucie, additional, Moonen, Martial, additional, Moutschen, Michel, additional, Van Regenmortel, Niels, additional, Ariën, Kevin K., additional, Barbezange, Cyril, additional, Betrains, Albrecht, additional, Garigliany, Mutien, additional, Engelen, Matthias M., additional, Gyselinck, Iwein, additional, Maes, Piet, additional, Schauwvlieghe, Alexander, additional, Liesenborghs, Laurens, additional, Belmans, Ann, additional, Verhamme, Peter, additional, and Meyfroidt, Geert, additional

Published
2021
Full Text
View/download PDF

47. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data

Author

Nguyen, Dung, primary, Simmonds, Peter, additional, Steenhuis, Maurice, additional, Wouters, Elise, additional, Desmecht, Daniel, additional, Garigliany, Mutien, additional, Romano, Marta, additional, Barbezange, Cyril, additional, Maes, Piet, additional, Van Holm, Bram, additional, Mendoza, Joaquín, additional, Oyonarte, Salvador, additional, Fomsgaard, Anders, additional, Lassaunière, Ria, additional, Zusinaite, Eva, additional, Resman Rus, Katarina, additional, Avšič-Županc, Tatjana, additional, Reimerink, Johan HJ, additional, Brouwer, Fiona, additional, Hoogerwerf, Marieke, additional, Reusken, Chantal BEM, additional, Grodeland, Gunnveig, additional, Le Cam, Sophie, additional, Gallian, Pierre, additional, Amroun, Abdennour, additional, Brisbarre, Nadège, additional, Martinaud, Christophe, additional, Leparc Goffart, Isabelle, additional, Schrezenmeier, Hubert, additional, Feys, Hendrik B, additional, van der Schoot, C Ellen, additional, and Harvala, Heli, additional

Published
2021
Full Text
View/download PDF

48. Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.

Author

UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, Misset, Benoît, Hoste, Eric, Donneau, Anne Françoise, Grimaldi, David, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Garigliany, Mutien, Najdovski, Tome, Laterre, Pierre-François, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, Misset, Benoît, Hoste, Eric, Donneau, Anne Françoise, Grimaldi, David, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Garigliany, Mutien, Najdovski, Tome, and Laterre, Pierre-François

Abstract

Correction to: BMC Pulm Med (2020) 20:317 10.1186/s12890-020-01361-x Following publication of the original article [1], it was brought to the authors’ attention that sentences in the method section were not appropriate, due to an omission in the update of a prior version.

Published
2021

49. Association between convalescent plasma treatment and mortality in COVID-19:a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U.H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L.M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre François, Lim, Lyn Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V.N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md M., Rahman, Md S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y.C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P.A., Hemkens, Lars G., Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U.H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L.M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre François, Lim, Lyn Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V.N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md M., Rahman, Md S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y.C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P.A., and Hemkens, Lars G.

Abstract

Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX). Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evi

Published
2021

50. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

Author

Devos, Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tome, Romano, Márta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler, Lucie, Moonen, Martial, Moutschen, Michel, Van Regenmortel, Niels, Ariën, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias, Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, Meyfroidt, Geert, Devos, Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tome, Romano, Márta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler, Lucie, Moonen, Martial, Moutschen, Michel, Van Regenmortel, Niels, Ariën, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias, Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, and Meyfroidt, Geert

Abstract

Background Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness. Methods In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study. Results Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%). Conclusions Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results